Zimmer Biomet Holdings Stock News

Zimmer Biomet is about to spin off its dental and spine business, and the transaction is expected to unlock value for shareholders.

Related Stocks: MRVL , TSM , INCY , QS , ZBH , XOM , ENJY , AI , ILMN , NLY , CRWD , COP , ETN , DOCU , VEEV , ROK ,

Wednesday''s top analyst upgrades and downgrades included Advanced Micro Devices, Annaly Capital Management, Clorox, Constellation Energy, Li Auto, Penn National Gaming, Teladoc Health, Transocean and Zimmer Biomet.

Several Wall Street analysts lowered their price targets for Zimmer Biomet, a day after release Q4 2021 earnings results that missed on both the top and bottom lines.

Upgrades According to Consumer Edge Research, the prior rating for The Hain Celestial Group Inc (NASDAQ:HAIN) was changed from Equal-Weight to Overweight. For the second quarter, Hain Celestial Group

Zimmer Biomet Holdings (NYSE: ZBH ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 6 2 0 Last 30D 2 2 2 1 0 1M Ago 1 0 1 1 0 2M Ago 1 0 3 0 0 3M Ago 2 0 0 0 0 These 16 analysts have an average price target of $137.81 versus the current price of Zimmer Biomet Holdings at $111.54, implying upside. Below is a summary of how these 16 analysts rated Zimmer Biomet Holdings over the past 3 months. The greater the number of bullish ratings, the Full story available on Benzinga.com

Zimmer Biomet Holdings Inc (ZBH) shares closed 4.2% lower than its previous 52 week low, giving the company a market cap of $25B. The stock is currently down 3.3% year-to-date, down 22.8% over the past 12 months, and up 8.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Trading volume this week was 18.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -59.9% The company's stock price performance over the past 12 months lags the peer average by -370.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -2.2% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Stocks that traded heavily or had substantial price changes Monday: Spirit Airlines, Tyson Foods rise; Cerence, Zimmer fall

Zimmer Biomet Holdings Inc. (NYSE:ZBH) Q4 2021 Results Earnings Conference Call February 07 2022, 08:30 AM ET Company Participants Keri Mattox - Senior Vice President Investor Relations…

https://www.investing.com/news/stock-market-news/zimmer-biomet-tumbles-as-covid-weighs-on-sales-of-devices-2758617

Stocks Analysis by Zacks Investment Research covering: Henry Schein Inc, Zimmer Biomet Holdings Inc, Allscripts Healthcare Solutions Inc, Healthcare Services Group Inc. Read Zacks Investment Research''s latest article on Investing.com

According to Zimmer Biomet (ZBH), both Q4 net sales and earnings metrics are negatively impacted by China VBP in Knees, Hips and S.E.T. product categories.

Zimmer Biomet Holdings Inc. (ZBH) CEO Bryan Hanson on Q4 2021 Results - Earnings Call Transcript

Zimmer Biomet Holdings Inc. that ZimVie Inc., the wholly owned subsidiary that is being spun off into a separate, publicly traded company will have $1.0 billion in revenue in 2022, which will be about the same as 2021. ZimVie, which is expected to begin trading as a standalone entity on March 1, is also expected to have adjusted earnings per share of $2.10 to $2.30 in 2022. Zimmer Biomet had announced in February 2021 it''s intent to spin off its spine and dental businesses. The company said it will retain 19.7% of the outstanding shares of ZimView once it goes public. Zimmer shares, which shed 4.4% in morning trading, have tumbled 17.1% over the past three months, while the S&P 500 has eased 3.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.